These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 36936932)

  • 21. Advances in immunotherapy for hepatocellular carcinoma.
    Sangro B; Sarobe P; Hervás-Stubbs S; Melero I
    Nat Rev Gastroenterol Hepatol; 2021 Aug; 18(8):525-543. PubMed ID: 33850328
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune cell infiltration and immunotherapy in hepatocellular carcinoma.
    Jiang Y; Lin L; Lv H; Zhang H; Jiang L; Ma F; Wang Q; Ma X; Yu S
    Math Biosci Eng; 2022 May; 19(7):7178-7200. PubMed ID: 35730302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A cellular senescence-related classifier based on a tumorigenesis- and immune infiltration-guided strategy can predict prognosis, immunotherapy response, and candidate drugs in hepatocellular carcinoma.
    Luo Y; Liu H; Fu H; Ding GS; Teng F
    Front Immunol; 2022; 13():974377. PubMed ID: 36458010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The interactions between major immune effector cells and Hepatocellular Carcinoma: A systematic review.
    Schoenberg MB; Li X; Li X; Han Y; Börner N; Koch D; Guba MO; Werner J; Bazhin AV
    Int Immunopharmacol; 2021 Dec; 101(Pt A):108220. PubMed ID: 34673334
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunotherapeutic approaches in Hepatocellular carcinoma: Building blocks of hope in near future.
    Minaei N; Ramezankhani R; Tamimi A; Piryaei A; Zarrabi A; Aref AR; Mostafavi E; Vosough M
    Eur J Cell Biol; 2023 Mar; 102(1):151284. PubMed ID: 36584598
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Highlighting novel targets in immunotherapy for liver cancer.
    Ruff SM; Shannon AH; Beane JD; Pawlik TM
    Expert Rev Gastroenterol Hepatol; 2022; 16(11-12):1029-1041. PubMed ID: 36404729
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy: Current Status and Future Perspectives.
    Floudas CS; Brar G; Greten TF
    Dig Dis Sci; 2019 Apr; 64(4):1030-1040. PubMed ID: 30830521
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma.
    Guo J; Tang Q
    Cancer Gene Ther; 2021 Nov; 28(10-11):1075-1087. PubMed ID: 33500535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunotherapy of hepatocellular carcinoma: recent progress and new strategy.
    Li J; Xuan S; Dong P; Xiang Z; Gao C; Li M; Huang L; Wu J
    Front Immunol; 2023; 14():1192506. PubMed ID: 37234162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Idarubicin-loaded biodegradable microspheres enhance sensitivity to anti-PD1 immunotherapy in transcatheter arterial chemoembolization of hepatocellular carcinoma.
    Zheng Z; Ma M; Han X; Li X; Huang J; Zhao Y; Liu H; Kang J; Kong X; Sun G; Sun G; Kong J; Tang W; Shao G; Xiong F; Song J
    Acta Biomater; 2023 Feb; 157():337-351. PubMed ID: 36509402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A novel spontaneous hepatocellular carcinoma mouse model for studying T-cell exhaustion in the tumor microenvironment.
    Liu YT; Tseng TC; Soong RS; Peng CY; Cheng YH; Huang SF; Chuang TH; Kao JH; Huang LR
    J Immunother Cancer; 2018 Dec; 6(1):144. PubMed ID: 30526672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy.
    Patel K; Lamm R; Altshuler P; Dang H; Shah AP
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32942580
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma.
    Chen Y; Hu H; Yuan X; Fan X; Zhang C
    Front Immunol; 2022; 13():896752. PubMed ID: 35757756
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma.
    Xu Y; Liao W; Luo Q; Yang D; Pan M
    Front Immunol; 2022; 13():761046. PubMed ID: 35145517
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Advances in Pharmacotherapy of Hepatocellular Carcinoma: A State-of-the-Art Review.
    Reiter FP; Ben Khaled N; Ye L; Zhang C; Seidensticker M; Op den Winkel M; Denk G; Geier A; De Toni EN
    Dig Dis; 2022; 40(5):565-580. PubMed ID: 34644705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Engineering T cells for immunotherapy of primary human hepatocellular carcinoma.
    Caraballo Galva LD; Cai L; Shao Y; He Y
    J Genet Genomics; 2020 Jan; 47(1):1-15. PubMed ID: 32089500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination Immunotherapy for Hepatocellular Carcinoma: Where Are We Currently?
    Uson Junior PLS; Nagalo BM; Ahn DH; Bekaii-Saab T; Borad MJ
    Semin Liver Dis; 2021 May; 41(2):136-141. PubMed ID: 33957697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Key oncogenic signaling pathways affecting tumor-infiltrating lymphocytes infiltration in hepatocellular carcinoma: basic principles and recent advances.
    Wang X; Yuan Z; Li Z; He X; Zhang Y; Wang X; Su J; Wu X; Li M; Du F; Chen Y; Deng S; Zhao Y; Shen J; Yi T; Xiao Z
    Front Immunol; 2024; 15():1354313. PubMed ID: 38426090
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review.
    Oura K; Morishita A; Tani J; Masaki T
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071550
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune cell therapy for hepatocellular carcinoma.
    Mizukoshi E; Kaneko S
    J Hematol Oncol; 2019 May; 12(1):52. PubMed ID: 31142330
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.